You are here
AFC and AMH Most Promising Predictors of Ovarian Reserve
October 22, 2012
A new report issued by the American Society for Reproductive Medicine Practice Committee expresses concern with lack of validated ovarian testing results.
The report, entitled “Testing and interpreting measures of ovarian reserve”, states there is “not yet a uniformly accepted definition of decreased ovarian reserve (DOR)” and concludes that screening tests are not sufficient enough to establish a diagnosis of DOR. The Committee also declares that tests designed for home use “have serious limitations and pitfalls”. The Antral Follicle Count (AFC) and antimullerian hormone (AMH) tests are the most promising of all available tests.
Currently, decreased ovarian reserve is defined as the presence of normal menses, but reproductive capacity and ability to respond to ovarian stimulating drugs is reduced or impaired compared to other women in the same age group. The Committee is exploring the concept of ovarian reserve as a function of the number and quality of remaining oocytes, or eggs, though they have yet to reach consensus on the most useful determining factor of fertility and DOR.
The Committee concludes that evidence is stacked against using any one ovarian reserve test as the sole criteria for using assisted reproductive technologies (ART). Furthermore, the combined results of these tests are also not more useful than any one test alone. AFC and AMH hold the most potential in regards to diagnostic measures.